Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Articles Tagged With:

  • Rosuvastatin vs Atorvastatin

    Rosuvastatin is a new statin whose efficacy was compared to that of atorvastatin in 623 patients with heterozygous familial hypercholesterolemia.
  • Arrhythmia Risk Stratification in Idiopathic Dilated Cardiomyopathy

    In this paper, Grimm and colleagues report on the usefulness of noninvasive testing to predict risk for arrhythmias in patients with idiopathic dilated cardiomyopathy.
  • Inflammation and Atrial Fibrillation

    This study reports the association between inflammation as measured by C-reactive protein and the prevalence and development of atrial fibrillation.
  • Clinical Briefs in Primary Care Supplement

  • Full August 1, 2004 Issue in PDF

  • Market Updates

    Daniel Schultz, MD, acting director of the FDAs Center for Devices and Radiological Health (CDRH) since April, last month had the acting term removed from his title by acting FDA Commissioner Lester Crawford. In announcing the appointment of Schultz to head CDRH, the agencys medical device unit, Crawford said he brings to our medical device program the ideal combination of skills, experience and temperament to ensure that FDAs medical device program is second to none.
  • Do you provide good care in dental emergencies?

    While working in the ED one night, a nurse noticed a strange feeling around her left cheek.
  • Agreements

    CompuMed (Los Angeles, California), a medical informatics company serving healthcare with diagnostic software solutions, said that it has been awarded a five-year renewal of its contract to provide electrocardiogram (ECG) interpretation systems and services for the New York State Department of Correctional Services (NYDOCS). NYDOCS will purchase a minimum of 87 new CardioGram systems along with ongoing ECG remote interpretation services.
  • Acquisitions

    Escalon Medical (Wayne, Pennsylvania) reported that the board of Drew Scientific Group (London) has recommended that its shareholders accept Escalons revised exchange offer.
  • Report from Europe

    Acusphere (Watertown, Massachusetts) said last month that it has entered into a collaboration, license and supply agreement with Nycomed (Roskilde, Denmark) for the European development and marketing rights to Acuspheres lead product candidate, AI-700, an ultrasound contrast agent currently in Phase III clinical trials for assessing myocardial perfusion in the diagnosis of coronary heart disease.